| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis, Knee | 37 | 2022 | 374 | 6.940 |
Why?
|
| Lupus Erythematosus, Systemic | 36 | 2023 | 190 | 6.240 |
Why?
|
| Osteoarthritis | 22 | 2021 | 330 | 5.470 |
Why?
|
| Arthritis, Rheumatoid | 22 | 2021 | 259 | 3.960 |
Why?
|
| Quality of Life | 19 | 2023 | 629 | 2.610 |
Why?
|
| Knee Joint | 22 | 2020 | 753 | 2.480 |
Why?
|
| Humans | 178 | 2023 | 27074 | 2.360 |
Why?
|
| Rheumatology | 11 | 2022 | 85 | 2.260 |
Why?
|
| Creatine Kinase | 5 | 2015 | 19 | 1.990 |
Why?
|
| Myositis | 5 | 2015 | 33 | 1.920 |
Why?
|
| Osteoarthritis, Hip | 11 | 2020 | 106 | 1.910 |
Why?
|
| Pain | 16 | 2022 | 413 | 1.880 |
Why?
|
| Antirheumatic Agents | 11 | 2020 | 85 | 1.870 |
Why?
|
| Arthralgia | 5 | 2019 | 134 | 1.810 |
Why?
|
| Rheumatic Diseases | 6 | 2021 | 53 | 1.780 |
Why?
|
| Female | 104 | 2021 | 15214 | 1.770 |
Why?
|
| Middle Aged | 82 | 2021 | 8925 | 1.740 |
Why?
|
| Severity of Illness Index | 25 | 2019 | 879 | 1.740 |
Why?
|
| Gait | 20 | 2020 | 412 | 1.710 |
Why?
|
| Male | 93 | 2019 | 14774 | 1.550 |
Why?
|
| Surveys and Questionnaires | 16 | 2023 | 1144 | 1.540 |
Why?
|
| Hip Joint | 10 | 2016 | 544 | 1.450 |
Why?
|
| Shoes | 5 | 2016 | 33 | 1.430 |
Why?
|
| Foot Orthoses | 5 | 2020 | 12 | 1.390 |
Why?
|
| Tuberculosis | 5 | 2013 | 19 | 1.380 |
Why?
|
| Chondrosarcoma | 23 | 2008 | 43 | 1.380 |
Why?
|
| Body Image | 5 | 2014 | 27 | 1.370 |
Why?
|
| Adult | 64 | 2019 | 7833 | 1.350 |
Why?
|
| Immunoglobulin G | 8 | 2013 | 80 | 1.350 |
Why?
|
| Immunosuppressive Agents | 7 | 2017 | 120 | 1.320 |
Why?
|
| Antibodies, Monoclonal | 8 | 2017 | 177 | 1.290 |
Why?
|
| Disease Management | 3 | 2021 | 102 | 1.250 |
Why?
|
| Weight-Bearing | 16 | 2014 | 158 | 1.240 |
Why?
|
| Arthritis, Psoriatic | 3 | 2017 | 14 | 1.130 |
Why?
|
| Hyaluronic Acid | 4 | 2022 | 55 | 1.110 |
Why?
|
| Pain Measurement | 11 | 2019 | 483 | 1.100 |
Why?
|
| Arthritis, Infectious | 3 | 2017 | 51 | 1.090 |
Why?
|
| Publishing | 3 | 2023 | 34 | 1.070 |
Why?
|
| Muscle Strength | 6 | 2019 | 130 | 1.050 |
Why?
|
| Ankle Joint | 5 | 2019 | 43 | 1.050 |
Why?
|
| Health Status Indicators | 4 | 2016 | 72 | 1.000 |
Why?
|
| Vibration | 5 | 2018 | 27 | 0.990 |
Why?
|
| Glucocorticoids | 4 | 2021 | 68 | 0.980 |
Why?
|
| Aged | 46 | 2021 | 8998 | 0.970 |
Why?
|
| Etanercept | 8 | 2017 | 21 | 0.970 |
Why?
|
| Lupus Nephritis | 2 | 2021 | 27 | 0.960 |
Why?
|
| Orthotic Devices | 6 | 2020 | 24 | 0.950 |
Why?
|
| Aspartate Aminotransferases | 2 | 2015 | 14 | 0.940 |
Why?
|
| Alanine Transaminase | 2 | 2015 | 15 | 0.940 |
Why?
|
| Rheumatologists | 4 | 2020 | 15 | 0.940 |
Why?
|
| Spondylitis, Ankylosing | 3 | 2010 | 20 | 0.930 |
Why?
|
| Health Status | 10 | 2018 | 218 | 0.890 |
Why?
|
| Radiography | 15 | 2016 | 619 | 0.880 |
Why?
|
| Reproducibility of Results | 15 | 2021 | 676 | 0.880 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2014 | 5 | 0.880 |
Why?
|
| Pain Management | 6 | 2018 | 143 | 0.870 |
Why?
|
| Proprioception | 3 | 2014 | 20 | 0.850 |
Why?
|
| Bone Density | 6 | 2011 | 144 | 0.810 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2022 | 9 | 0.810 |
Why?
|
| Exercise Therapy | 5 | 2020 | 88 | 0.800 |
Why?
|
| Joints | 5 | 2009 | 69 | 0.800 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 77 | 0.770 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 7 | 0.760 |
Why?
|
| Biomechanical Phenomena | 14 | 2020 | 644 | 0.730 |
Why?
|
| Cartilage | 5 | 2023 | 107 | 0.720 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 37 | 0.720 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2020 | 501 | 0.710 |
Why?
|
| Platelet-Rich Plasma | 1 | 2022 | 87 | 0.700 |
Why?
|
| Nerve Growth Factor | 2 | 2017 | 36 | 0.690 |
Why?
|
| Treatment Outcome | 17 | 2022 | 3485 | 0.690 |
Why?
|
| Leg | 4 | 2008 | 50 | 0.680 |
Why?
|
| Analgesics | 2 | 2020 | 79 | 0.680 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2008 | 189 | 0.680 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 20 | 0.670 |
Why?
|
| Nerve Growth Factors | 1 | 2020 | 38 | 0.660 |
Why?
|
| Research Design | 1 | 2021 | 185 | 0.660 |
Why?
|
| Injections, Intra-Articular | 4 | 2022 | 95 | 0.640 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2017 | 17 | 0.640 |
Why?
|
| Retrospective Studies | 15 | 2019 | 3538 | 0.630 |
Why?
|
| Patient Acuity | 1 | 2018 | 8 | 0.610 |
Why?
|
| Cartilage, Articular | 5 | 2021 | 418 | 0.610 |
Why?
|
| Bone Neoplasms | 13 | 2008 | 130 | 0.590 |
Why?
|
| Cross-Sectional Studies | 11 | 2019 | 891 | 0.580 |
Why?
|
| Patient Outcome Assessment | 2 | 2014 | 38 | 0.570 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 21 | 0.560 |
Why?
|
| Keratan Sulfate | 5 | 2006 | 20 | 0.550 |
Why?
|
| Dermatomyositis | 2 | 2014 | 12 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 261 | 0.540 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 79 | 0.530 |
Why?
|
| Walking | 3 | 2008 | 253 | 0.520 |
Why?
|
| Prednisone | 2 | 2015 | 66 | 0.490 |
Why?
|
| Mortality, Premature | 1 | 2015 | 6 | 0.490 |
Why?
|
| Foot | 2 | 2019 | 44 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2017 | 85 | 0.490 |
Why?
|
| Methylprednisolone | 1 | 2015 | 20 | 0.490 |
Why?
|
| Leadership | 1 | 2016 | 92 | 0.490 |
Why?
|
| United States | 11 | 2020 | 2036 | 0.480 |
Why?
|
| Paracentesis | 1 | 2015 | 3 | 0.470 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2015 | 115 | 0.470 |
Why?
|
| Fluoroscopy | 1 | 2015 | 48 | 0.460 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2014 | 2 | 0.450 |
Why?
|
| Psychometrics | 9 | 2018 | 220 | 0.450 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2005 | 10 | 0.450 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2014 | 3 | 0.440 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 38 | 0.440 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 131 | 0.430 |
Why?
|
| Somatosensory Disorders | 2 | 2018 | 11 | 0.420 |
Why?
|
| Vasculitis | 2 | 2009 | 26 | 0.420 |
Why?
|
| Dermatology | 1 | 2012 | 6 | 0.410 |
Why?
|
| Disease Progression | 10 | 2013 | 673 | 0.410 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 14 | 0.400 |
Why?
|
| Risk Factors | 10 | 2021 | 2302 | 0.400 |
Why?
|
| Synovial Fluid | 5 | 2011 | 92 | 0.400 |
Why?
|
| Receptors, Tumor Necrosis Factor | 7 | 2013 | 27 | 0.400 |
Why?
|
| Caregivers | 1 | 2015 | 197 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2006 | 110 | 0.390 |
Why?
|
| Arthritis, Experimental | 3 | 2019 | 49 | 0.380 |
Why?
|
| Isoniazid | 2 | 2009 | 3 | 0.370 |
Why?
|
| Touch | 2 | 2008 | 8 | 0.370 |
Why?
|
| Methotrexate | 2 | 2009 | 38 | 0.370 |
Why?
|
| Range of Motion, Articular | 7 | 2019 | 708 | 0.360 |
Why?
|
| Pilot Projects | 4 | 2014 | 420 | 0.340 |
Why?
|
| Benchmarking | 1 | 2010 | 32 | 0.340 |
Why?
|
| Sensory Thresholds | 4 | 2012 | 22 | 0.340 |
Why?
|
| Quadriceps Muscle | 1 | 2010 | 34 | 0.340 |
Why?
|
| Knee | 1 | 2010 | 45 | 0.340 |
Why?
|
| Hand Joints | 2 | 2020 | 3 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 333 | 0.340 |
Why?
|
| Demography | 1 | 2010 | 72 | 0.330 |
Why?
|
| Glucosamine | 1 | 2009 | 4 | 0.330 |
Why?
|
| Transaminases | 1 | 2009 | 6 | 0.330 |
Why?
|
| Income | 1 | 2010 | 80 | 0.330 |
Why?
|
| Proteoglycans | 5 | 1994 | 140 | 0.320 |
Why?
|
| Cohort Studies | 7 | 2019 | 1890 | 0.310 |
Why?
|
| Language | 4 | 2021 | 63 | 0.310 |
Why?
|
| Self Report | 6 | 2023 | 223 | 0.310 |
Why?
|
| Cost of Illness | 3 | 2019 | 50 | 0.300 |
Why?
|
| Biomarkers | 5 | 2017 | 562 | 0.300 |
Why?
|
| Liver | 1 | 2009 | 145 | 0.300 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 474 | 0.290 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 132 | 0.290 |
Why?
|
| Double-Blind Method | 9 | 2016 | 406 | 0.290 |
Why?
|
| Immunoconjugates | 1 | 2008 | 7 | 0.290 |
Why?
|
| Anthropometry | 2 | 2007 | 34 | 0.280 |
Why?
|
| Scleroderma, Systemic | 2 | 2005 | 8 | 0.280 |
Why?
|
| Joint Deformities, Acquired | 1 | 2007 | 1 | 0.280 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 4777 | 0.280 |
Why?
|
| Reference Values | 3 | 2014 | 186 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 15 | 2004 | 129 | 0.260 |
Why?
|
| Braces | 2 | 2020 | 23 | 0.260 |
Why?
|
| Matrix Metalloproteinase 1 | 3 | 2005 | 6 | 0.250 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2006 | 69 | 0.250 |
Why?
|
| Adalimumab | 4 | 2019 | 16 | 0.250 |
Why?
|
| Body Height | 4 | 2007 | 34 | 0.240 |
Why?
|
| Animals | 9 | 2020 | 3642 | 0.240 |
Why?
|
| Antitubercular Agents | 4 | 2013 | 12 | 0.240 |
Why?
|
| Femur Head Necrosis | 1 | 2005 | 7 | 0.240 |
Why?
|
| Chondrocytes | 6 | 2007 | 150 | 0.240 |
Why?
|
| Cross-Cultural Comparison | 4 | 2013 | 39 | 0.240 |
Why?
|
| Acetabulum | 1 | 2007 | 229 | 0.230 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 46 | 0.220 |
Why?
|
| Polymyositis | 2 | 2014 | 8 | 0.220 |
Why?
|
| Cyclophosphamide | 2 | 2003 | 48 | 0.220 |
Why?
|
| Adaptation, Psychological | 2 | 2015 | 175 | 0.220 |
Why?
|
| Young Adult | 7 | 2015 | 1995 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2014 | 1792 | 0.210 |
Why?
|
| Anniversaries and Special Events | 1 | 2023 | 3 | 0.210 |
Why?
|
| Case-Control Studies | 3 | 2014 | 587 | 0.210 |
Why?
|
| Diclofenac | 1 | 2003 | 3 | 0.210 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 139 | 0.210 |
Why?
|
| Doxorubicin | 2 | 2000 | 57 | 0.210 |
Why?
|
| Prognosis | 6 | 2019 | 785 | 0.200 |
Why?
|
| Time Factors | 9 | 2019 | 1433 | 0.200 |
Why?
|
| Acetaminophen | 1 | 2003 | 24 | 0.200 |
Why?
|
| Glycosaminoglycans | 4 | 1994 | 22 | 0.200 |
Why?
|
| Arthroplasty, Replacement, Hip | 4 | 2005 | 810 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 6 | 2006 | 94 | 0.200 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 114 | 0.200 |
Why?
|
| Kidney | 1 | 2003 | 153 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2014 | 625 | 0.190 |
Why?
|
| Socioeconomic Factors | 3 | 2015 | 302 | 0.190 |
Why?
|
| Pneumococcal Infections | 1 | 2021 | 7 | 0.190 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 10 | 0.190 |
Why?
|
| Quality of Health Care | 3 | 2023 | 102 | 0.190 |
Why?
|
| Raynaud Disease | 1 | 2001 | 1 | 0.190 |
Why?
|
| Infliximab | 3 | 2013 | 17 | 0.190 |
Why?
|
| Gene Expression | 2 | 2013 | 199 | 0.190 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2019 | 133 | 0.180 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 4 | 0.180 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 5 | 0.180 |
Why?
|
| Paclitaxel | 2 | 2002 | 50 | 0.180 |
Why?
|
| Coronary Disease | 1 | 2001 | 50 | 0.180 |
Why?
|
| Radiography, Interventional | 1 | 2021 | 17 | 0.180 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2000 | 1 | 0.180 |
Why?
|
| Gene Expression Profiling | 5 | 2013 | 139 | 0.180 |
Why?
|
| Longitudinal Studies | 5 | 2015 | 1368 | 0.180 |
Why?
|
| Patient Care Planning | 1 | 2021 | 39 | 0.180 |
Why?
|
| Chicago | 4 | 2019 | 950 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 2 | 2019 | 15 | 0.170 |
Why?
|
| Selenium | 1 | 2000 | 10 | 0.170 |
Why?
|
| Awards and Prizes | 1 | 2000 | 21 | 0.170 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 348 | 0.170 |
Why?
|
| Adolescent | 8 | 2019 | 2172 | 0.170 |
Why?
|
| Foundations | 1 | 2020 | 1 | 0.170 |
Why?
|
| Mycobacterium Infections | 1 | 2019 | 2 | 0.170 |
Why?
|
| Mycobacterium haemophilum | 1 | 2019 | 2 | 0.170 |
Why?
|
| Mediastinal Diseases | 1 | 2019 | 4 | 0.170 |
Why?
|
| Antibodies, Antinuclear | 3 | 2017 | 12 | 0.170 |
Why?
|
| Tuberculin Test | 3 | 2009 | 9 | 0.170 |
Why?
|
| Uveitis, Anterior | 1 | 2019 | 3 | 0.160 |
Why?
|
| Spondylarthropathies | 1 | 2019 | 4 | 0.160 |
Why?
|
| Health Impact Assessment | 1 | 2019 | 4 | 0.160 |
Why?
|
| Artificial Limbs | 1 | 2019 | 6 | 0.160 |
Why?
|
| Azacitidine | 1 | 2019 | 10 | 0.160 |
Why?
|
| Absorptiometry, Photon | 4 | 2011 | 84 | 0.160 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 1999 | 4 | 0.160 |
Why?
|
| RNA, Messenger | 7 | 2007 | 310 | 0.160 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 7 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2003 | 637 | 0.160 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2018 | 15 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2022 | 211 | 0.150 |
Why?
|
| Checklist | 2 | 2016 | 33 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 18 | 0.150 |
Why?
|
| Observer Variation | 1 | 2018 | 96 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 30 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 245 | 0.150 |
Why?
|
| Spinal Cord | 1 | 1999 | 84 | 0.150 |
Why?
|
| Disability Evaluation | 3 | 2019 | 264 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 1998 | 5 | 0.150 |
Why?
|
| Chronic Pain | 1 | 2020 | 134 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 1998 | 9 | 0.150 |
Why?
|
| Hyperalgesia | 1 | 2018 | 44 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2019 | 161 | 0.140 |
Why?
|
| Liver Function Tests | 1 | 2017 | 20 | 0.140 |
Why?
|
| Tenascin | 3 | 2002 | 4 | 0.140 |
Why?
|
| RNA, Small Interfering | 3 | 2007 | 81 | 0.140 |
Why?
|
| Europe | 2 | 2018 | 58 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 123 | 0.140 |
Why?
|
| Immunotherapy | 2 | 2008 | 58 | 0.140 |
Why?
|
| Viral Load | 1 | 2017 | 69 | 0.140 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 122 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2017 | 105 | 0.140 |
Why?
|
| Arthroplasty | 1 | 1998 | 150 | 0.140 |
Why?
|
| United Kingdom | 2 | 2010 | 47 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 27 | 0.140 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 56 | 0.140 |
Why?
|
| Stress, Mechanical | 2 | 2007 | 157 | 0.140 |
Why?
|
| Arthritis, Juvenile | 2 | 2009 | 7 | 0.130 |
Why?
|
| Linear Models | 2 | 2014 | 248 | 0.130 |
Why?
|
| Sex Factors | 4 | 2018 | 464 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2009 | 17 | 0.130 |
Why?
|
| Culture | 2 | 2013 | 24 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 161 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2016 | 38 | 0.130 |
Why?
|
| Journalism, Medical | 1 | 2016 | 2 | 0.130 |
Why?
|
| Body Weight | 3 | 2006 | 134 | 0.130 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 595 | 0.130 |
Why?
|
| Apoptosis | 3 | 2013 | 213 | 0.130 |
Why?
|
| Age Factors | 2 | 2012 | 766 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 111 | 0.130 |
Why?
|
| Fatigue | 1 | 2016 | 57 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2015 | 7 | 0.120 |
Why?
|
| Pulse Therapy, Drug | 1 | 2015 | 3 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 52 | 0.120 |
Why?
|
| Metatarsophalangeal Joint | 1 | 2015 | 5 | 0.120 |
Why?
|
| Movement | 3 | 2006 | 112 | 0.120 |
Why?
|
| Depression | 1 | 2019 | 444 | 0.120 |
Why?
|
| Professional-Patient Relations | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cosmetic Techniques | 1 | 2014 | 5 | 0.120 |
Why?
|
| Antigens, Neoplasm | 2 | 2007 | 41 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 1112 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2007 | 56 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2015 | 59 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2008 | 116 | 0.110 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2014 | 2 | 0.110 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2014 | 2 | 0.110 |
Why?
|
| Microscopic Polyangiitis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2014 | 2 | 0.110 |
Why?
|
| Models, Biological | 3 | 2011 | 322 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2014 | 18 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2014 | 26 | 0.110 |
Why?
|
| Hospitals, University | 2 | 2012 | 23 | 0.110 |
Why?
|
| Physicians | 2 | 2015 | 122 | 0.110 |
Why?
|
| Physical Examination | 2 | 2022 | 116 | 0.110 |
Why?
|
| Creatinine | 1 | 2014 | 42 | 0.110 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2006 | 458 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 137 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2014 | 74 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 300 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2014 | 24 | 0.110 |
Why?
|
| Abatacept | 2 | 2017 | 6 | 0.110 |
Why?
|
| Cattle | 4 | 2009 | 130 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2004 | 32 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2014 | 84 | 0.110 |
Why?
|
| Cystitis | 1 | 1993 | 12 | 0.110 |
Why?
|
| Latent Tuberculosis | 1 | 2013 | 2 | 0.100 |
Why?
|
| Quebec | 1 | 2013 | 3 | 0.100 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 20 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2019 | 107 | 0.100 |
Why?
|
| Hospitals, County | 1 | 2012 | 4 | 0.100 |
Why?
|
| Prevalence | 3 | 2019 | 443 | 0.100 |
Why?
|
| Phenotype | 5 | 2004 | 312 | 0.100 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 30 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 292 | 0.100 |
Why?
|
| Cell Division | 3 | 2002 | 86 | 0.100 |
Why?
|
| Self-Assessment | 1 | 2012 | 29 | 0.100 |
Why?
|
| Self Concept | 1 | 2012 | 37 | 0.100 |
Why?
|
| Sensation Disorders | 1 | 2012 | 10 | 0.100 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2011 | 2 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 96 | 0.100 |
Why?
|
| Cell Line, Tumor | 6 | 2008 | 256 | 0.090 |
Why?
|
| Canada | 3 | 2018 | 47 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 3 | 0.090 |
Why?
|
| Incidence | 1 | 2014 | 759 | 0.090 |
Why?
|
| Perception | 1 | 2012 | 77 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 57 | 0.090 |
Why?
|
| Mass Screening | 1 | 2013 | 167 | 0.090 |
Why?
|
| Morphogenesis | 1 | 1991 | 8 | 0.090 |
Why?
|
| Afferent Pathways | 1 | 2010 | 4 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 216 | 0.090 |
Why?
|
| Muscle Weakness | 1 | 2010 | 34 | 0.090 |
Why?
|
| Teaching | 2 | 2022 | 51 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 9 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2011 | 1778 | 0.080 |
Why?
|
| Pressure | 1 | 2010 | 64 | 0.080 |
Why?
|
| Turkey | 2 | 2013 | 6 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 176 | 0.080 |
Why?
|
| Menisci, Tibial | 1 | 2012 | 174 | 0.080 |
Why?
|
| Horses | 1 | 2009 | 10 | 0.080 |
Why?
|
| Cytokines | 1 | 2011 | 222 | 0.080 |
Why?
|
| Social Environment | 1 | 2010 | 76 | 0.080 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2012 | 196 | 0.080 |
Why?
|
| Dogs | 1 | 2009 | 167 | 0.080 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 1061 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2009 | 108 | 0.080 |
Why?
|
| Rabbits | 1 | 2009 | 182 | 0.080 |
Why?
|
| Tendon Injuries | 1 | 2012 | 207 | 0.080 |
Why?
|
| Intervertebral Disc Chemolysis | 1 | 1989 | 7 | 0.080 |
Why?
|
| Extremities | 1 | 2008 | 27 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 293 | 0.080 |
Why?
|
| Chordoma | 1 | 2008 | 9 | 0.080 |
Why?
|
| DNA, Neoplasm | 3 | 2004 | 23 | 0.080 |
Why?
|
| Posture | 2 | 2006 | 63 | 0.080 |
Why?
|
| Orthopedic Procedures | 1 | 2012 | 309 | 0.080 |
Why?
|
| Endopeptidases | 3 | 1996 | 21 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2019 | 333 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 30 | 0.070 |
Why?
|
| Rats | 1 | 2009 | 664 | 0.070 |
Why?
|
| Intervertebral Disc Displacement | 1 | 1989 | 85 | 0.070 |
Why?
|
| Rituximab | 1 | 2008 | 48 | 0.070 |
Why?
|
| Bone Diseases, Developmental | 1 | 2007 | 1 | 0.070 |
Why?
|
| HLA-A1 Antigen | 1 | 2007 | 1 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 11 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 31 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 11 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 23 | 0.070 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2007 | 19 | 0.070 |
Why?
|
| Protein Kinase C-delta | 1 | 2007 | 10 | 0.070 |
Why?
|
| Alternative Splicing | 3 | 2002 | 22 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 29 | 0.070 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 5 | 0.070 |
Why?
|
| Schizosaccharomyces pombe Proteins | 2 | 1996 | 2 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1996 | 11 | 0.070 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2006 | 30 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 164 | 0.060 |
Why?
|
| Autoantigens | 1 | 2006 | 26 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 1996 | 102 | 0.060 |
Why?
|
| Exercise Test | 1 | 2006 | 118 | 0.060 |
Why?
|
| Emotions | 2 | 2017 | 72 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2001 | 29 | 0.060 |
Why?
|
| ADAMTS13 Protein | 1 | 2005 | 5 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 11 | 0.060 |
Why?
|
| Child | 5 | 2019 | 1295 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2005 | 40 | 0.060 |
Why?
|
| Cells, Cultured | 5 | 2007 | 520 | 0.060 |
Why?
|
| Hypoxia | 1 | 2004 | 32 | 0.060 |
Why?
|
| Abstracting and Indexing as Topic | 1 | 2004 | 1 | 0.060 |
Why?
|
| MEDLINE | 1 | 2004 | 5 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2007 | 443 | 0.060 |
Why?
|
| Therapeutic Irrigation | 1 | 2004 | 56 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2004 | 32 | 0.060 |
Why?
|
| Alcoholism | 1 | 2005 | 67 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 75 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 72 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 62 | 0.060 |
Why?
|
| Tibia | 1 | 2006 | 245 | 0.060 |
Why?
|
| RNA, Antisense | 1 | 2003 | 2 | 0.060 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2003 | 6 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 15 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2004 | 169 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 599 | 0.050 |
Why?
|
| Extracellular Matrix | 3 | 2008 | 53 | 0.050 |
Why?
|
| Translations | 2 | 2013 | 9 | 0.050 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2003 | 2 | 0.050 |
Why?
|
| Peritonitis | 1 | 2003 | 17 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 18 | 0.050 |
Why?
|
| Telomerase | 1 | 2002 | 10 | 0.050 |
Why?
|
| Femur Head | 1 | 2003 | 69 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 2 | 2013 | 56 | 0.050 |
Why?
|
| Biopsy | 1 | 2003 | 201 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2002 | 15 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2003 | 158 | 0.050 |
Why?
|
| Mice | 2 | 2019 | 1395 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 77 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2022 | 30 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 33 | 0.050 |
Why?
|
| Fibronectins | 1 | 2001 | 19 | 0.050 |
Why?
|
| Collagen | 2 | 2008 | 86 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 5 | 0.050 |
Why?
|
| Alendronate | 1 | 2001 | 7 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2001 | 11 | 0.040 |
Why?
|
| Ethambutol | 1 | 2000 | 1 | 0.040 |
Why?
|
| Mycobacterium | 1 | 2000 | 1 | 0.040 |
Why?
|
| Pyrazinamide | 1 | 2000 | 1 | 0.040 |
Why?
|
| Streptomycin | 1 | 2000 | 1 | 0.040 |
Why?
|
| Rifampin | 1 | 2000 | 3 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2001 | 47 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 35 | 0.040 |
Why?
|
| Plasmapheresis | 2 | 1999 | 13 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2000 | 5 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 2 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2001 | 43 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 12 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 87 | 0.040 |
Why?
|
| England | 1 | 2020 | 14 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2001 | 96 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 6 | 0.040 |
Why?
|
| Cell Size | 1 | 2000 | 7 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2000 | 11 | 0.040 |
Why?
|
| Amino Acids | 1 | 2000 | 19 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 39 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 24 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 39 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 13 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 161 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2001 | 133 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2022 | 206 | 0.040 |
Why?
|
| Staphylococcal Protein A | 1 | 1999 | 2 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1999 | 16 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2000 | 91 | 0.040 |
Why?
|
| Lactones | 1 | 1999 | 9 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 58 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2004 | 120 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1999 | 18 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1999 | 27 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 11 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2000 | 260 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2019 | 23 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 72 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 72 | 0.040 |
Why?
|
| Quadriplegia | 1 | 1999 | 8 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 10 | 0.040 |
Why?
|
| Femur Neck | 1 | 1999 | 21 | 0.040 |
Why?
|
| Chromatography, Ion Exchange | 3 | 1994 | 7 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 102 | 0.040 |
Why?
|
| Mentors | 1 | 2019 | 36 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2018 | 13 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 54 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 112 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 78 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2013 | 147 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2019 | 73 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2013 | 170 | 0.040 |
Why?
|
| Workload | 1 | 2018 | 29 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 44 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 198 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2019 | 44 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2019 | 56 | 0.040 |
Why?
|
| Hip | 1 | 1999 | 67 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 347 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2017 | 53 | 0.030 |
Why?
|
| Epitopes | 2 | 2007 | 46 | 0.030 |
Why?
|
| Diathermy | 1 | 1997 | 1 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 64 | 0.030 |
Why?
|
| DNA Primers | 3 | 2004 | 52 | 0.030 |
Why?
|
| Osteonecrosis | 1 | 2017 | 16 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2019 | 490 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 30 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2003 | 366 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 1997 | 74 | 0.030 |
Why?
|
| Illinois | 1 | 2017 | 250 | 0.030 |
Why?
|
| Mental Health | 1 | 2017 | 108 | 0.030 |
Why?
|
| Independent Living | 1 | 2019 | 322 | 0.030 |
Why?
|
| Chromatography, Gel | 2 | 1994 | 9 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 108 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 409 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 329 | 0.030 |
Why?
|
| Software | 1 | 2015 | 61 | 0.030 |
Why?
|
| Exercise | 1 | 2019 | 450 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 552 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2007 | 118 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 328 | 0.030 |
Why?
|
| Goals | 1 | 2014 | 43 | 0.030 |
Why?
|
| Arthrography | 2 | 2006 | 29 | 0.030 |
Why?
|
| Clone Cells | 2 | 1991 | 11 | 0.030 |
Why?
|
| Cell Movement | 2 | 2005 | 80 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2007 | 107 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 1544 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2013 | 3 | 0.030 |
Why?
|
| Transfection | 2 | 2003 | 121 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 17 | 0.030 |
Why?
|
| Polyarteritis Nodosa | 1 | 1993 | 1 | 0.030 |
Why?
|
| Necrosis | 1 | 1993 | 26 | 0.030 |
Why?
|
| Inflammation | 1 | 2015 | 272 | 0.030 |
Why?
|
| Latin America | 1 | 2013 | 5 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 100 | 0.030 |
Why?
|
| Histones | 1 | 2013 | 32 | 0.030 |
Why?
|
| Philippines | 1 | 2013 | 4 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 149 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 53 | 0.030 |
Why?
|
| Hemorrhage | 1 | 1993 | 81 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2003 | 31 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 83 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 175 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 85 | 0.020 |
Why?
|
| Chondroitin Lyases | 1 | 1992 | 1 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1992 | 2 | 0.020 |
Why?
|
| Trypsin | 1 | 1992 | 4 | 0.020 |
Why?
|
| Electrochemistry | 1 | 1992 | 43 | 0.020 |
Why?
|
| Denmark | 1 | 2012 | 10 | 0.020 |
Why?
|
| Sweden | 1 | 2012 | 9 | 0.020 |
Why?
|
| Feedback | 1 | 2012 | 33 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 482 | 0.020 |
Why?
|
| Base Sequence | 2 | 2002 | 109 | 0.020 |
Why?
|
| Metabolism | 1 | 2011 | 6 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 55 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 1991 | 7 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 90 | 0.020 |
Why?
|
| Cell Line | 1 | 1991 | 273 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2011 | 79 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2002 | 69 | 0.020 |
Why?
|
| Femoral Neoplasms | 1 | 1990 | 4 | 0.020 |
Why?
|
| Self-Examination | 1 | 2009 | 3 | 0.020 |
Why?
|
| Chymopapain | 1 | 1989 | 7 | 0.020 |
Why?
|
| Chromosome Aberrations | 2 | 2001 | 17 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 1 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1987 | 2 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2007 | 5 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2007 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 21 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2007 | 14 | 0.020 |
Why?
|
| DNA | 1 | 1987 | 106 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 14 | 0.020 |
Why?
|
| Cell Survival | 1 | 2007 | 121 | 0.020 |
Why?
|
| Viscosity | 1 | 2006 | 10 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 50 | 0.020 |
Why?
|
| Ligaments, Articular | 1 | 1988 | 110 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 34 | 0.020 |
Why?
|
| Elasticity | 1 | 2006 | 30 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2007 | 81 | 0.020 |
Why?
|
| Actins | 1 | 2006 | 34 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 102 | 0.020 |
Why?
|
| Purine-Nucleoside Phosphorylase | 2 | 1996 | 2 | 0.020 |
Why?
|
| Chromosome Banding | 2 | 1996 | 4 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 1996 | 7 | 0.020 |
Why?
|
| Ploidies | 2 | 1996 | 8 | 0.020 |
Why?
|
| Risk | 2 | 2004 | 204 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 1996 | 16 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2006 | 38 | 0.020 |
Why?
|
| Cognition | 1 | 2014 | 1339 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2005 | 10 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 18 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2005 | 19 | 0.010 |
Why?
|
| Genes, myc | 1 | 2004 | 8 | 0.010 |
Why?
|
| Genome | 1 | 2004 | 10 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2004 | 19 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 36 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 10 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 37 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2004 | 4 | 0.010 |
Why?
|
| Information Storage and Retrieval | 1 | 2004 | 2 | 0.010 |
Why?
|
| Culture Techniques | 2 | 1994 | 21 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 137 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2003 | 1 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2003 | 2 | 0.010 |
Why?
|
| Integrins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Collagen Type II | 1 | 2003 | 22 | 0.010 |
Why?
|
| Collagenases | 1 | 2003 | 15 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 60 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 99 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 158 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 105 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 6 | 0.010 |
Why?
|
| Chondroma | 1 | 2002 | 6 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 8 | 0.010 |
Why?
|
| Prednisolone | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 2002 | 12 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 44 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 47 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2002 | 40 | 0.010 |
Why?
|
| K562 Cells | 1 | 2002 | 3 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 23 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 1982 | 12 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 156 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 195 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 73 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2001 | 32 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Genes, p16 | 1 | 2001 | 4 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 65 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2001 | 84 | 0.010 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 1999 | 1 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 12 | 0.010 |
Why?
|
| Sulfones | 1 | 1999 | 20 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 342 | 0.010 |
Why?
|
| Reoperation | 1 | 2002 | 925 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 916 | 0.010 |
Why?
|
| Interferons | 1 | 1996 | 8 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1996 | 14 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1996 | 36 | 0.010 |
Why?
|
| Fees, Medical | 1 | 1975 | 1 | 0.010 |
Why?
|
| Public Opinion | 1 | 1975 | 5 | 0.010 |
Why?
|
| Financing, Organized | 1 | 1975 | 8 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1994 | 5 | 0.010 |
Why?
|
| Cesium | 1 | 1994 | 14 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1994 | 26 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 27 | 0.010 |
Why?
|
| Culture Media | 1 | 1994 | 32 | 0.010 |
Why?
|
| Chlorides | 1 | 1994 | 25 | 0.010 |
Why?
|
| Immunoassay | 1 | 1994 | 38 | 0.010 |
Why?
|
| Tritium | 1 | 1994 | 9 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 1994 | 9 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1994 | 9 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1994 | 9 | 0.010 |
Why?
|
| Sulfates | 1 | 1994 | 5 | 0.010 |
Why?
|
| Alginates | 1 | 1994 | 11 | 0.010 |
Why?
|
| Proline | 1 | 1994 | 8 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1994 | 5 | 0.010 |
Why?
|
| Gels | 1 | 1994 | 14 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1975 | 144 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1999 | 383 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1994 | 76 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 65 | 0.010 |
Why?
|
| Tensile Strength | 1 | 1988 | 25 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1988 | 175 | 0.000 |
Why?
|
| Hypergammaglobulinemia | 1 | 1987 | 2 | 0.000 |
Why?
|
| Plasminogen | 1 | 1982 | 1 | 0.000 |
Why?
|
| Hemostasis | 1 | 1982 | 9 | 0.000 |
Why?
|
| Antithrombin III | 1 | 1982 | 4 | 0.000 |
Why?
|
| Blood Coagulation Factors | 1 | 1982 | 19 | 0.000 |
Why?
|
| Thrombosis | 1 | 1982 | 54 | 0.000 |
Why?
|
| New York | 1 | 1975 | 10 | 0.000 |
Why?
|
| Financing, Government | 1 | 1975 | 9 | 0.000 |
Why?
|
| Attitude | 1 | 1975 | 34 | 0.000 |
Why?
|
| Consumer Behavior | 1 | 1975 | 23 | 0.000 |
Why?
|